BBZA.DE • XETRA
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold BBZA.DE in your mock portfolio yet.
The negative EPS of -8.60 and a PE ratio of -5.88 indicate that BB Biotech AG is currently loss-making, reflecting weak underlying financial performance. This suggests profitability challenges and likely volatility in earnings driven by its biotech investment portfolio. Without evidence of improving earnings trends, the current fundamentals lean clearly negative.
The stock has risen 4.9% over the last month and trades well above its 200-day moving average of €38.92 at a current price of €50.60, indicating a strong medium-term uptrend. An RSI of 66.19 shows positive momentum that is approaching overbought territory but not yet extreme. Overall, price action and technicals are supportive of a bullish near- to medium-term view, albeit with some risk of consolidation after the recent run-up.
Alternative data for BB Biotech AG is modest and relatively flat, with low web traffic, no active hiring, and small, mostly stagnant social media followings. These signals do not point to strong growth in investor or customer engagement, but they also do not show a sharp deterioration. Overall, alternative data is more indicative of a niche, stable presence rather than a rapidly scaling or collapsing story.
BB Biotech AG shows bullish technical momentum with the share price trading well above its 200-day moving average and positive short-term performance, but this is offset by clearly negative earnings and muted alternative data signals. The current setup suggests a technically driven rally on a fundamentally weak earnings base, with limited evidence of accelerating business or investor engagement outside the market price. Overall, the balance of factors supports a neutral stance, with upside tied mainly to continued market momentum and portfolio performance rather than improving core fundamentals.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: